Related Experiment Video
Updated: May 14, 2026
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Castrate-resistant prostate cancer: postdocetaxel management.
1Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA 98109, USA.
Current Opinion in Urology
|January 25, 2013
Summary
Recent advancements offer new treatments for metastatic castrate-resistant prostate cancer (CRPC) after docetaxel. Multiple novel agents now provide survival benefits, changing CRPC management.
Area of Science:
- Oncology
- Medical Therapeutics
- Prostate Cancer Research
Background:
- Docetaxel was the sole survival-prolonging treatment for metastatic castrate-resistant prostate cancer (CRPC) before 2010.
- Recent years have seen significant progress in CRPC treatment options.
Purpose of the Study:
- To review novel therapeutic agents for CRPC following docetaxel treatment.
- To highlight survival improvements and FDA approvals in the postdocetaxel setting.
Main Methods:
- Review of preclinical research and clinical trials for novel CRPC agents.
- Analysis of agents including cabazitaxel, abiraterone, enzalutamide, radium-223, and sipuleucel-T.
Main Results:
- Cabazitaxel is an FDA-approved next-generation taxane for postdocetaxel CRPC.
- Abiraterone and enzalutamide target androgen synthesis and signaling pathways.
- Radium-223 (radionuclide) and sipuleucel-T (immunotherapy) show survival benefits in CRPC.
Conclusions:
- The management of CRPC has been transformed by new life-prolonging therapies.
- Optimal sequencing and coordination of these agents are crucial for patient outcomes.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...